57 results about "High intraocular pressure" patented technology

Assemblies and methods for modifying an intraocular pressure of a patient's one or both eyes are disclosed. The assemblies and methods can be used to treat, inhibit, or prevent ocular conditions such as glaucoma, high intraocular pressure, optic disc edema, idiopathic intracranial hypertension, zero-gravity induced papilledema, and other optic pressure related conditions. An assembly can include a goggle including at least one cavity, a pump in fluid communication with the at least one cavity, and a control mechanism. The control mechanism can be operatively coupled to the pump and can maintain a target pressure or target pressure range in the at least one cavity, which, when the assembly is worn by a patient, is the area between a patient's eye(s) and wall surfaces of the goggle. Controlling the pressure over the outer surfaces of the patient's eye(s) can drive a desired change in the intraocular pressure of the eye(s).

The invention relates to a point eye mask and a preparation and application thereof, the point eye mask comprises a back lining layer, a drug storage layer and a protective layer, wherein, the drug storage layer is formed by coating the drug emulsion containing PSA (pressure sensitive adhesive), skin transdermal enhancer and other drugs onto the back lining layer, wherein, the drug emulsion is formed by blending nano-powder of Chinese herbal extract for szechwan lovage rhizome, radix salviae miltiorrhizae, angelica sinensis, chrysanthemum, plantago asiatica, semen celosiae, cuscuta chinensis lam, equisetum hiemale linne, fructus ligustri lucidi, radix glycyrrhiza, and cassia seed and the like; a polyester film protective layer is covered onto the back lining layer, and the eye mask is formed through cutting. The point eye mask adopts principles of traditional Chinese acupuncture and release and control technology of modern transdermal, can constantly release active ingredients in points for a long period of time, can well adjust and improve muscles, nerves, and blood vessels at and around the eyes, can play a certain role in delaying for development of myopia of young people, and play a role in treatment for fatigue blurred vision, high intraocular pressure, presbyopia, and dry eye syndrome. Meanwhile, the invention has advantages of convenient using, persistent efficacy.

An ophthalmic composition comprises active vitamin D as an effective component and is used for preventing deterioration of the optical transparency, occurrence of high intraocular pressure diseases or defective sight, observed after an ophthalmic operation, due to hyperplasia of the anterior ocular cells in the tissues damaged by the ophthalmic operation, which are in course of a healing process, and/or excess production of cellular materials.The ophthalmic composition can be dropped in the eye after operations such as those for cataract, for transplantation of intraocular lenses and for cornea to maintain the intraocular transparency of the anterior ocular region, to control the hyperplasia of the anterior ocular cells in the tissues damaged by the ophthalmic operation, which are in course of a healing process, and/or excess production of cellular materials and to thus prevent any reduction of visual acuity.

The present invention relates to an improved process for the production of prostaglandins and prostaglandin analogs. In particular, this invention relates to the production of prostaglandins of the PGF_2α-series, including latanoprost, travoprost, and bimatoprost, which are active pharmaceutical ingredients used for the reduction of elevated intra-ocular pressure in patients with glaucoma and ocular hypertension.

The invention belongs to the field of pharmacy, and relates to application of sodium valproate in preparation of medicaments for treating or improving optic nerve pathological changes of glaucoma. The in-vitro cell culture experiment and in-vivo animal experiment indicate that sodium valproate with certain concentration can promote retina ganglionic cells (RGCs) cultured in vitro to survive and enhance the extension capacity of the axon, and can lower the expression of proapoptotic gene BAX and promote the RGCs to survive under the conditions of chronic high intraocular pressure, thereby relieving the damage of RGCs. The experiments prove that the sodium valproate can protect the RGCs in the aspects of multiple pathogeneses of glaucoma optic nerve pathological changes, and further more, can be used as an active ingredient for preaprating medicaments for treating glaucoma optic nerve pathological changes, especially medicaments for protecting RGCs. The invention has important application value and favorable social and economic benefits in clinical treatment of glaucoma.

An implanted intraocular shunt can be manually manipulated, without surgical intervention, to modify the flow resistance of the shunt, thereby providing relief from high intraocular pressure while avoiding hypotony. For example, through the application of pressure along a surface of the eye, a portion of the shunt can be displaced or separated relative to the shunt, thereby decreasing the flow resistance of the shunt.

The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or α2 macgroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or α2 macgroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or α2 macgroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.

The invention discloses a device combining a sensor and the SS-OCT technology to test intraocular pressure. The device comprises the sensor, optical coherence tomography equipment and a linear platform and is characterized in that the sensor is arranged right above to-be-tested eyeballs, the to-be-tested eyeballs are placed on the linear platform, the linear platform drives the to-be-tested eyeballs to move forwards and backwards to regulate the distance between the eyeballs and the sensor; the optical coherence tomography equipment comprises a scanning lens, and the corneas of the to-be-tested eyeballs are regulated to the focal length of the scanning lens during testing. The device has the advantages that nondestructive high intraocular pressure detection is achieved, and the sensor is high in sensitivity; compared with a traditional method, the device can detect micro-force allowing the corneas to deform and acquire precise cornea applanation area and is more accurate.

The invention provides application of an aminoadamantane mononitrate compound in preparation of drugs for preventing and treating diseases such as glaucoma, vascular dementia, subarachnoid hemorrhage and pulmonary arterial hypertension. Discovered by experiments, the aminoadamantane mononitrate compound can be combined with an NMDA receptor and release nitric oxide (NO), excitatory toxicity of nerve cells induced by glutamic acid can be lowered, the compound plays a role in dilating cerebral blood vessels, cerebral blood flow can be improved, but peripheral blood pressure is not lowered; retinal ganglion cell injury induced by high intraocular pressure can be reduced, and the intraocular pressure is lowered through releasing the NO; in a vascular dementia model, the cerebral blood flow can be improved, motor behavior disorder is relieved, and learning cognitive ability is improved; behavioral abnormality and cerebrovascular spasm induced by subarachnoid hemorrhage can be relieved; discovered by researches on tissue distribution of the drugs, MN-08 can be gathered in pulmonary tissue, in a pulmonary arterial hypertension model, pulmonary blood vessels can be dilated, right ventricular pressure can be lowered, and plumpness of right ventricle can be reduced.

The invention relates to a traditional Chinese medicine preparation for treating glaucoma and high intraocular pressure, which is composed of the following 14 granular concentrated traditional Chinese medicines: the amount of granular concentrated traditional Chinese medicines are: each of the gypsum, equisetum, balloonflower root radix bupleuri, hooked uncaria, cleaver herb, chamomile, burrerfly bush flower, ledebouriella root, astragalus, nutgrass flatsedge and alismatis rhizome is 15-25 weight parts; each of the licorice and dried orange peel is 5-10 weight parts. In which, each granular concentrated traditional Chinese medicine is concentrated by the same ratio (e.g. 5:1) by weight; the preparation form is oral granular traditional Chinese medicine preparation. Sight can be restored at soonest in 30 days by taking the traditional Chinese medicine preparation of the present invention; no bad feeling occurs during the medicine taken period; and no recurrence is found in the 5 years follow-up survey after cured; consequently, the invention provides a medicament with low price, no side effect and substantial effect to the glaucoma and high intraocular pressure patients.

The invention discloses a microporous drainage device for ophthalmic surgery and a conveying system thereof. The drainage device comprises a drainage valve body, wherein the drainage valve body is provided with a fixing part, a first drainage part and a second drainage part; the first drainage part is arranged on one side of the fixing part and is used for being inserted into an anterior chamber tubule of an eyeball of a patient; the second drainage part is arranged on the other side, opposite to the first drainage part, of the fixing part and is used for being connected with a vein tubule of the eyeball of the patient; and a microporous drainage channel is formed in the drainage valve body. The conveying system of the microporous drainage device for the ophthalmic surgery comprises a hollow handheld rod, wherein an operating head and a pull wire rod are respectively arranged at two ends of the handheld rod; a suture penetrates through the handheld rod and is provided with a closed annular part and a pull wire part; the closed annular part is embedded into the operating head; and the pull wire part is fixed with the pull wire rod. According to the microporous drainage device for the ophthalmic surgery, the problem of high intraocular pressure of glaucoma can be solved, and various inflammation problems caused by implantation of a common drainage valve are avoided, so that the glaucoma disease is safely and efficiently treated.

Glaucoma is an eye disease with intra-ocular pressure being discontinuously or continuously increased, continuous intraocular hypertension can damage all part tissues of an eyeball and visual function, and if the continuous intraocular hypertension is not treated in time, visual field can be lost completely to cause blindness. Glaucoma is one of three major leading blind eye disorders causing blindness of human, the incidence of total population is 1 percent, and the incidence of people more than 45 years old is 2 percent. The drug is prepared by combining tribulus terrestris, bear gall, cassia seed, Chinese gentian, glycine max, whitebackleaf mallotus root, gastrodia tuber, celosia seed, gambirplant, butterflybush flower, red ochre, pipewort, cinnabar, ptunella spike, magnet, chastetree fruit, dragon's bone, chrysanthemum flower, amber, mulberry leaf, seed of spine date, cicada skin, arboruitae seed, hedgehog skin, pearl, Korean raspberry, nacre, fruit of Chinese magnoliavine, abalone, flatstem astragalus seed, cuscuta chinensis and herb of snow of june, and the drugs are combined to ensure that efficacies of all the drugs generate a synergistic action, so that glaucoma can be effectively treated.

The invention discloses an establishment method for a chronic ocular hypertension and long ocular axis animal model. The establishment method comprises the following steps of S10, anesthetizing a model animal; S20, using a non-absorbable suture line for intermittently suturing a conjunctiva and a superficial sclera for a circle along the outer periphery of a cornea at a set distance; S30, tightening the suture line, and knotting and fixing; and S40, measuring intraocular pressure of the model animal within 5 minutes after knotting, and if the intraocular pressure is larger than 60 mmHg (1 mmHg = 0.133 kPa), the chronic ocular hypertension and long ocular axis animal model is obtained. The intraocular pressure of the model animal can be increased, ocular axis can be increased, and the method has the advantages of long intraocular pressure maintaining time, few ocular complications, simple operation and high operation success rate. In addition, the invention further discloses the chronic ocular hypertension and long ocular axis animal model and application thereof in research of glaucoma and myopia diseases.

A novel phakic intraocular lens implantation without viscoelastics and an instrument thereof. The special designed instrument is employed to achieve a purpose of maintaining an anterior chamber only with a perfusion liquid in the surgery, so as to get rid of the influence of the viscoelastics completely. The viscoelastics are not used, so that there is no need to inject the viscoelastics or remove the viscoelastics as in traditional methods, the surgery time is shortened such that total time of surgical procedures from incision construction to incision hydration can be reduced to only 1˜3 minutes, and viscoelastic-related complications, such as postoperative high intraocular pressure and lens opacity, are completely avoided.

The invention discloses a pigmented glaucoma animal model building method and application thereof. The method and the application thereof comprise the following steps: S1, selecting a rat model group; S2, preparing an iris pigment particle suspension; S3, performing measurement and data recording on intraocular pressure of the two groups of rats; and S4, performing optic neuropathology observation on the rats. According to a glaucoma animal model established by the invention, part of characteristics of human pigmented glaucoma can be conveniently and well simulated, and the obtained intraocular hypertension lasts for a long time; the method meets the pathological characteristics of pigmented glaucoma and the requirements of low cost, medium intraocular hypertension, long duration and stability of an optic nerve protection drug pharmacodynamic experimental animal model, has the characteristics of simplicity and convenience in operation and high success rate, and meets the establishment of a pigmented glaucoma model by medical science researchers.

The invention relates to the technical field of soft capsule preparation, and discloses a preparation process of a MitoQ blueberry anthocyanin soft capsule preparation formula, which comprises the following components in percentage by weight: 2-7% of MitoQ molecules, 15-35% of blueberry anthocyanin, 3-8% of xanthophyll, 1-3% of camellia-seed oil, 1-3% of beeswax and the balance of soybean lecithin, and the MitoQ molecules, the blueberry anthocyanin, the xanthophyll, the camellia-seed oil, the beeswax and the soybean lecithin are mixed according to the preparation ratio of the MitoQ molecules, the blueberry anthocyanin, the xanthophyll, the camellia-seed oil, the beeswax and the soybean lecithin. The ratio of the camellia seed oil is 50-70%, the ratio of the beewax is 1-6%, and the ratio of the soybean lecithin is 2-5%. The eye-protecting and eyesight-protecting mask has the effects of protecting eyes, protecting eyesight and the like, and is capable of changing new and repairing from the source, enabling cells to be full of vitality, accurately positioning damaged cells, directly reaching the internal penetration function, repairing oxidative damage for a long time, effectively removing free radicals in retina, filtering harmful blue light invasion and effectively relieving the problems of eye interference, eyestrain and high intraocular pressure.

The invention provides a method for detecting whether a retina is damaged or not. The method is characterized in that whether the retina is damaged or not is detected by detecting whether a synaptic vesicle protein exists in aqueous humor or not, the synaptic vesicle protein is a synaptic vesicle protein 2, and whether the synaptic vesicle protein 2 exists in the aqueous humor or not is detected by using a synaptic vesicle protein 2 antibody. According to the method for detecting whether the retina is damaged or not, whether the retina is damaged or not is detected by detecting whether the synaptic vesicle protein 2 exists in the aqueous humor or not, the method is an effective method for clinically detecting the damage degree of the retina suffering from high intraocular pressure damage,the occurrence of glaucoma can be effectively predicted, and therefore a basis is provided for preventing the glaucoma, and the morbidity of the glaucoma is lowered.

The invention discloses application of lauromacrogol in preparation of a chronic intraocular hypertension animal model. The chronic intraocular hypertension animal model can be constructed by injecting lauromacrogol into suprascleral veins of a model animal, especially an animal model with chronic mild intraocular pressure rise. The model construction method is simple, the intraocular hypertension maintaining time is long, and complications do not exist. The chronic intraocular hypertension animal model can be used for simulating the chronic intraocular pressure rising process of open-angle glaucoma of people, is suitable for animal experiment research of screening glaucoma treatment drugs and glaucoma pathogenesis research, and has the application value of preclinical research.